ROB HILL
CEO, TAE LIFE SCIENCES
WHY: Last year took over company that is aiming to use technology first developed at nuclear reactors to cure cancer in particularly dangerous areas like brain. Valuation in past year has risen from $300M to $400M.
IN THE NEWS: Participating in a possible groundbreaking trial in China to treat 80 patients who have neck and brain cancers that are recurring despite prior treatments.
NOTABLE: Big advantage will be delivering therapy in a single treatment where patients won’t need radiation for months and hence a cancer center could treat thousands of patients annually rather than hundreds.
QUOTABLE: “I’ve made it my life’s work to cure cancer. The thing I realized early in life is that cancer touches all of us. There’s no avoiding that reality. One in three people alive will get cancer at some point in their lives.”
